Mutual of America Capital Management LLC cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 12.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 41,033 shares of the specialty pharmaceutical company’s stock after selling 5,590 shares during the period. Mutual of America Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $5,311,000 as of its most recent filing with the SEC.
A number of other large investors have also added to or reduced their stakes in JAZZ. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Jazz Pharmaceuticals by 65.6% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 202 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 80 shares in the last quarter. ST Germain D J Co. Inc. acquired a new position in shares of Jazz Pharmaceuticals during the second quarter worth $40,000. Spire Wealth Management lifted its stake in shares of Jazz Pharmaceuticals by 128.6% in the 3rd quarter. Spire Wealth Management now owns 423 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 238 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of Jazz Pharmaceuticals by 58.1% during the 2nd quarter. Quadrant Capital Group LLC now owns 555 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 204 shares in the last quarter. Finally, Signaturefd LLC grew its position in Jazz Pharmaceuticals by 85.7% during the 3rd quarter. Signaturefd LLC now owns 546 shares of the specialty pharmaceutical company’s stock worth $71,000 after acquiring an additional 252 shares during the last quarter. Institutional investors and hedge funds own 88.15% of the company’s stock.
Insider Buying and Selling at Jazz Pharmaceuticals
In other news, Director Mark Douglas Smith sold 417 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $119.27, for a total transaction of $49,735.59. Following the transaction, the director now owns 6,888 shares of the company’s stock, valued at approximately $821,531.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.40% of the company’s stock.
Wall Street Analysts Forecast Growth
Jazz Pharmaceuticals Stock Up 0.6 %
Shares of NASDAQ:JAZZ opened at $123.43 on Monday. The company has a quick ratio of 1.67, a current ratio of 2.06 and a debt-to-equity ratio of 1.46. The stock has a market cap of $7.77 billion, a price-to-earnings ratio of 140.26, a PEG ratio of 0.94 and a beta of 0.62. The business’s 50 day moving average is $122.07 and its 200 day moving average is $127.82. Jazz Pharmaceuticals plc has a 12-month low of $111.25 and a 12-month high of $152.90.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.
- Five stocks we like better than Jazz Pharmaceuticals
- Find and Profitably Trade Stocks at 52-Week Lows
- Uber quadruples EPS estimates, but is growth decelerating?
- How to Invest in Hotel Stocks
- 3 stocks set to benefit from record Valentine’s Day spending
- What Do S&P 500 Stocks Tell Investors About the Market?
- Tradeweb is a disruptive pure play on financial market liquidity
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.